References
- Scott A. Dihydroergotamine: a review of its use in the treatment of migraines and other headaches. Clin Neuropharmacol 1992; 15:289–96
- Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55:754–62
- Goadsby PJ, Lipton RA, Ferrari MD. Migraine – current understanding and treatment. N Engl J Med 2002; 346:257–70
- Saper JR, Silberstein S, Dodick D, . DHE in the pharmacotherapy of migraine: potential for a larger role. Headache 2006; 46 (Suppl 4) S212–20
- Bobick A, Jennings G, Skews H, . Low oral bioavailability of dihydroergotamine and first-pass extraction with orthostatic hypotension. Clin Pharmacol Ther 1981; 30:673–9
- Schran HF, Tse FLS, Chang C-T. Bioequivalence and safety of subcutaneously and intramuscularly administered dihydroergotamine in healthy volunteers. Curr Ther Res 1994; 55:1501–8
- Saper JR, Silberstein S. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache 2006; 46:S171–81
- Borgström L, Bengtsson T, Derom E, . Variability in lung deposition of inhaled drug, within and between asthmatic patients, with a pMDI and a dry powder inhaler, Turbuhaler. Int J Pharm 2000; 193:227–30
- Newman SP. Principles of metered-dose inhaler design. Respir Care 2005; 50:1177–90
- Armer TA, Shrewsbury SB, Newman SP, . Aerosol delivery of ergotamine tartrate via a breath-synchronized plume-control inhaler in humans. Curr Med Res Opin 2007; 23:3177–87
- Shrewsbury SB, Cook RO, Taylor G, . Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel (Tempo™) inhaler. Headache 2008; 48:355–67
- Davey G, Sedgwick P, Maier W, . Association between migraine and asthma: matched case-control study. Br J Gen Pract 2002; 52:723–7
- Gurkan F, Ece A, Haspolat K, . Parental history of migraine and bronchial asthma in children. Allergol Immunopathol 2000; 28:15–7
- Shrewsbury SB, Armer TA, Newman SP, . Breath-synchronized plume-control inhaler for pulmonary delivery of fluticasone propionate. Int J Pharm. Jan 17, 2008. [Epub ahead of print]
- Aurora SK, Shrewsbury SB. Rapid and sustained clinical efficacy and safety of two doses of inhaled dihydroergotamine mesylate via a novel inhaler (Tempo™ inhaler). Presented at the American Headache Society Annual MeetingChicago, IllinoisJune, 2007
- Strachan DP, Butland BK, Anderson HR. Incidence and prognosis of asthma and wheezing illness from early childhood to age 33 in a national British cohort. BMJ 1996; 312:1195–9
- Chen TC, Leviton A. Asthma and eczema in children born to women with migraine. Arch Neurol 1990; 47:1227–30
- Ziegler DK, Hassanein RS, Couch JR. Characteristics of life headache histories in a non-clinic population. Neurology 1977; 27:265–9
- Anderson HR, Bailey PA, Cooper JS, . Morbidity and school absence caused by asthma and wheezing illness. Arch Dis Child 1983; 58:777–84
- Aamodt AH, Stovner LJ, Langhammer A, . Is headache related to asthma, hay fever, and chronic bronchitis? The Head-HUNT Study. Headache 2007; 47:204–12
- Ozge A, Ozge C, Oztark C, . The relationship between migraine and atopic disorders – the contribution of pulmonary function tests and immunological screening. Cephalalgia 2006; 26:172–9
- van Manen JG, Bindels PJ, Ijzermans CJ, . Prevalence of comorbidity in patients with a chronic airway obstruction and controls over the age of 40. J Clin Epidemiol 2001; 54:287–93
- Von Behren J, Kreutzer R, Hernandez A. Self-reported asthma prevalence in adults in California. J Asthma 2002; 39:429–40
- Shrewsbury SB, Kori S, Smith T, . Sustained pain relief in migraine is not necessarily dependent on the PK of a drug and does not have to be at the cost of rapid onset of relief. Poster (P07.041) at the American Academy of Neurology Annual Meeting. April, 2008